Abstract
1-INTRODUCTION
In the $1 trillion pharmaceutical and biotech industry, Pfizer has long been renowned for a robust research and development (R&D) department and an extensive product portfolio and has often enjoyed first-mover advantage (Yahoo Finance, 2016) . Exhibit 1 offers a snapshot of the firm's financial performance from 2008 to 2015. In 2014, revenues from its top five drugs-Enrbrel, Lyrica, Prevnar, Lipitor, and Celebrex-surpassed $23.1 billion and constituted 50 percent of Pfizer's revenues (IMAP, 2015; King, 2014; Loo, 2014 Loo, , 2015 Loo, , 2016 Ratty, 2015 Ratty, , 2016 . Sales surpassed $46.00 billion, with a profit of $8.99 billion and market value of $205.47 billion. In that same year, management decided to pursue a corporate inversion that would move its headquarters from New York to London. Corporate inversions have become popular among multinational corporations (MNCs) seeking favorable tax rates and cost savings (Avi-Yonah & Marian, 2015; Capurso, 2016; DeAngelis, 2015; Gapper, 2016) . Firms often pursue this strategy through mergers and acquisitions (M&As) to help them expand worldwide. Such arrangements may take the form of reverse triangular mergers, whereby a firm uses one of its subsidiaries to acquire another firm, in order to improve economies of scale (Kung, 2009) . This is what Pfizer intended to do in its acquisition of Astra Zeneca. Not all such plans come to fruition, however. The experiences of the American pharmaceutical giant-which failed in merging with UK-based AstraZeneca in 2014 and then with Allergan of Ireland in 2015-offer a case in point.
2-A LOOK AT PFIZER'S EXTRAORDINARY GROWTH
Pfizer's corporate history encompasses scientific discoveries, unique entrepreneurial initiatives, and wellplanned internationalization. Founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, Pfizer first began expanding when it started producing citric acid from sugar by using the process of mold fermentation. In 1906, com-pany sales surpassed $3 million. In 1928, Pfizer's researchers pursued the antibiotic properties of the penicillin mold, which led to a major breakthrough in medicine and put the company on secure financial footing. Subsequent accomplishments included the discovery of additional groups of antibiotics in the 1950s and 1960s, such as Terramycin (oxytetracycline) and Vibramycin (doxycycline hyclate), which made Pfizer a cash-rich company (Pfizer, 2015 In the 1980s, Pfizer saw its Feldene (piroxicam) become a leading anti-inflammatory medication, and in the 1990s, the company introduced Viagra (sildenafil citrate), which remains a blockbuster to this day. After Pfizer's merger with Warner-Lambert in 2000, the firm introduced an array of other profitable drugs that improved the lives of millions of consumers, including Geodon (ziprasidone hydro-chloride), Vfend (voriconazole), Relpax (eletriptan HBr), Caduet (amlodipine besylate and atorvastatin calcium), Sutent (sunitinib malate), Eraxis (anidulafungin), and Chantix (varenicline). These profit-able drugs burnished the company's reputation and helped Pfizer to remain a major MNC first-mover in the pharmaceutical industry.
3-A FOCUS ON CORE COMPETENCIES IN AN EVER-GROWING INDUSTRY
Exhibit 2 and Exhibit 3 provide financial data for Pfizer and its major competitors. In 2014, the global pharmaceutical industry's sales stood at $1 trillion versus $947.6 billion in 2013. The industry's 40 percent growth was attributed to the development of oncology, autoimmune, respiratory, and antiviral drugs (Loo, 2016) . Known for "high R&D intensity" (Wagner & Wakeman, 2016 , p. 1091 ) and well-established portfolios and value chains, the industry comprises mostly large firms from North America and the European Union. Corporate profits and margins in the biotech sector are among the highest: at 84.9 percent (Loo, 2016 Ever-increasing sales because of consumer demand and newmarkets in both developed and emerging markets also factor into these arrangements (Jack, 2006; Loo, 2014 Loo, , 2015 Loo, , 2016 
5-R&D TOWARD MEANINGFUL INNOVATIONS
The company's core competencies are its aggressive growth and investment and strategic partner-ships in the industry. In 2015, Pfizer spent $7.5 billion on R&D versus Novartis's $9.3 billion. The company's continued growth and scientific innovations have enhanced its standing in the industry and global visibility. Like other firms, in some cases Pfizer has boosted its R&D activities by col-laborating with well-known niche organizations that attracted promising markets (Statista, 2015) . These relationships included academic and global scouting partnerships and venture investments (Pfizer, 2015) .
6-FIRM-SPECIFIC INTERNATIONALIZATION AND GLOBAL STRATEGIES
Pfizer is an active player in international operations, R&D facilities, and value chains. The company maintains offices and subsidiaries in numerous countries, mostly in Western Europe, North America, and Japan. Pfizer is also active in emerging markets, which are helping to fuel future growth. In many instances, MNCs have sought out transnational or reverse triangular mergers whereby the acquiring MNCs establish new subsidiaries or entities and later have their agents in those organizations buy the target businesses. In this arrangement, the newly created subsidiaries are allowed to merge or become part of the target companies. This was the strategy that Pfizer intended to pursue in its acquisition of AstraZeneca in 2014-a strategy met with a chorus of criticism concerning job losses, weakened economic development, and expatriation of profits."The proposed takeover by Pfizer of AstraZeneca has engaged the public, enraged politicians, and triggered in some quarters a demand for legislation to frustrate foreign ownership," noted the Financial Times (Carr, 2014,p. 9). The US government as well as the local communities that would have been most affected by the relocation of Pfizer's R&D centers and headquarters were among the most vocal opponents. That heavy criticism was the main reason for the collapse of the merger. Another article in the Financial Times, titled "Politicians Have the Treatment for Pfizer Syndrome," noted that the practice of corporate inversion, "contributes to a corporate culture skewed to financial engineering. Buying and selling companies takes precedence over generating organic growth in the underlying businesses, which is where competitive advantage Usually lies" (Plender, 2014, p.7) . Because of "legal and ethical issues of corporate inversion" (Jeffers, 2014, p. 2), the US government initiated plans to overhaul its corporate tax system to reduce tax rates and pro-vide business with incentives to stay Sykes, 2014) . At the same time, the leaders and general public in affected countries and regions fret over losing tax revenues, R&D centers, and jobs (Jackman & Tretiak, 2014; Mann, 2005; Marian, 2015) when corporations exit (Hwang, 2015) . For some firms, however, moving headquarters to tax-friendly locations can be the only option to improve their financial health (Schmidt, Bates, & Paravano, 2015) . Specialization: The pharmaceutical sector has become crowded with niche companies that pursue specialized R&D and sell novel drugs. Size is a major factor in the industry and small firms are unable to compete because of high costs and scarce R&D resources. This brings competition and pressure on R&D and future drug portfolios. The global pharmaceutical and biotech industry is expected to grow in selected markets because of increased consumer demand and to fall off in other sectors because of limited opportunities, lackluster R&D performance, and the increased reliance on generic, as opposed to brand-name, drugs (Loo, 2014 (Loo, , 2015 (Loo, , and 2016 . In developed economies, the population is aging faster than it is in developing countries and emerging markets. This could create growth opportunities for MNCs but strain national healthcare systems. In the next ten years, the world population is expected to grow, mostly in the emerging markets and developing countries (Loo, 2014 (Loo, , 2015 . Consequently, pharmaceutical firms will look to exploit opportunities in emerging markets and developing economies. In the face of shifting and increasing competition, the pharmaceutical sector may witness additional large-scale transnational or reverse triangular mergers that could significantly alter the industry profile. While Pfizer remains a successful MNC, it will likely continue to explore the possibility of additional acquisitions and selected collaborations with other pharmaceutical and biotech companies. Because of its size, financial strength, and wellbalanced product portfolio, analysts believe that Pfizer is in a good position to expand globally. The value and far-reaching effects of corporate inversions, which was brought to the fore by Pfizer's previous experiences, continues to be debated, both in the United States and abroad. 
7-THE QUEST FOR CORPORATE INVERSION

